Ireland· IE-PA-EU/1/22/1646/001-003
Amifampridine SERB 10 mg tablets
A amifampridine product containing amifampridine phosphate, registered in Ireland by SERB S.A.. The same ATC class is registered in 16 of our 19 countries.
Checked against HPRA (Ireland) on
Informational only — not a medical device.
Where it is registered
Amifampridine is registered in 16 of 19 countries.
Countries holding a registration under ATC N07XX05 (amifampridine), each read from that country’s own register.
- This record: Ireland, from HPRA (Ireland)
- 9 of them publish a price we can compare per daily dose
Amifampridine · ATC N07XX05
16 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Germany
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Sweden
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of amifampridine costs, country by country.
Normalised to the WHO defined daily dose (40 mg), the median price runs from $75.59 in Switzerland to $3657.38 in France — a ×48 gap.
- 2 markets with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Amifampridine · price per daily dose (40 mg)
USD · FX 28 Sept 2026
- FR France$3657.38
- CH Switzerland$75.59
The record
At a glance
HPRA (Ireland)- Active substance
- Amifampridine Phosphate
- Manufacturer
- SERB S.A.
- Country
- Ireland (IE)
- ATC code
- N07XX05
- ATC class
- Amifampridine
- Defined daily dose
- 40 mg, O
- Reimbursed
- Not published by this register
- Source register
- HPRA (Ireland)
- Last checked
- September 28, 2026
Packs & prices · 1
- ie_pa_numberEU/1/22/1646/001-003
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
82 interactions on record for amifampridine.
Graded by severity as the source publishes them — 4 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Amifampridine · interactions on record
82 records
- 4 severe
- 78 moderate
Most severe, free to view
- BupropionN06AX12severe
- BupropionN07BA02severe
- IohexolV08AB02severe
- IopamidolV08AB04severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Amifampridine in 14 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- NetherlandsAmifampridine Accord 10 mg tablettenAccord Healthcare B.V.
- United Kingdom3,4-Diaminopyridine 10mg tabletsSpecial Order
- CzechiaAMIFAMPRIDINE SERBSERB S.A., Brusel
- PolandAmifampridine Medical ValleyMedical Valley Invest AB
- FranceAMIFAMPRIDINE SERB 10 mg, compriméSERB (BELGIQUE)
- FinlandAmifampridine SERBSERB S.A.
- CanadaFIRDAPSEKYE PHARMACEUTICALS INC.
- IcelandAmifampridine SERBSERB S.A.
Authorised across Europe · EMA
The same active substance is authorised in 11 EEA countries. Names it is sold under:
- Germany · Amifampridin Accord, Amifampridin Amarox
- France · Amifampridine Amarox, Amifampridine Biogaran
- Hungary · Amifampridine Accord
- Iceland · Amifampridine Serb, Firdapse
- Italy · Amifampridina Accord
- Liechtenstein · Amifampridine Serb, Firdapse
- Netherlands · Amifampridine Accord, Amifampridine Amarox
- Norway · Amifampridin Medical Valley, Amifampridine Accord
- Poland · Amifampridine Medical Valley
- Portugal · Amifampridina Accord, Amifampridina Generis
- Slovenia · Amifampridin Accord
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of HPRA (Ireland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/25b9d2b4-7843-45f5-aece-473a3c17a9e0 GET /v1/drugs/25b9d2b4-7843-45f5-aece-473a3c17a9e0?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Tablet",
"routes": [
"Oral use"
],
"source": "hpra",
"atc_all": [
"N07XX05"
],
"strength": null,
"pa_number": "EU/1/22/1646/001-003",
"substances": [
"Amifampridine Phosphate"
],
"legal_basis": "Generic application (Article 10(1) of Directive No 2001/83/EC)",
"market_info": "Unknown",
"authorised_at": "19/05/2022",
"dispensing_status": "Product subject to prescription which may not be renewed (A)",
"registration_status": "AU",
"supply_legal_status": "Supply through pharmacies only",
"interchangeable_code": null
}See everything about amifampridine.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.